The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma

BACKGROUND: Novel agents (NAs) such as thalidomide and bortezomib have been administered in combination with autologous stem-cell transplantation (ASCT) to effectively treat multiple myeloma (MM). However, whether NAs perform better as induction treatments prior to transplantation, or as post-transp...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Min, Chang-Ki, Lee, Sung-Eun, Yahng, Seung-Ah, Cho, Byung-Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Kim, Hee-Je, Lee, Seok, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong-Wook, Min, Woo-Sung, Park, Chong-Won
פורמט: Artigo
שפה:Inglês
יצא לאור: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2013
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3786280/
https://ncbi.nlm.nih.gov/pubmed/24086940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2013.48.3.198
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים